Exploration of Novel Metabolic Features Reflecting Statin Sensitivity in Lung Cancer Cells

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Statins, cholesterol-lowering drugs, show anti-cancer effects by inhibiting HMGCR.
• Cancer cell susceptibility to statins varies, with E-cadherin potentially indicating sensitivity.
• Molecular differences between statin-sensitive and resistant cancer cells are not fully understood.

Purpose of the Study:

• To identify novel parameters influencing statin sensitivity in lung cancer cells.
• To compare gene expression and metabolite profiles of statin-sensitive and resistant cell lines.
• To elucidate the impact of statin treatment on cellular cholesterol and CoA metabolism.

Main Methods:

• Comparative analysis of gene expression profiles in lung cancer cell lines.
• Metabolite content analysis, focusing on CoA and cholesterol precursors.
• Assessment of atorvastatin's effect on specific gene expression (PANK2, SOAT1) and cholesterol ester ratios.

Main Results:

• Statin-sensitive cells (HOP-92) exhibited lower cholesterol synthesis gene expression and initial CoA/HMG-CoA levels compared to resistant cells (NCI-H322M).
• Atorvastatin reduced mRNA expression of PANK2 (CoA synthesis enzyme) and SOAT1 (cholesterol esterification enzyme).
• Atorvastatin treatment decreased the cholesterol ester to total cholesterol ratio in statin-sensitive cells.

Conclusions:

• Statin-sensitive cancer cells may have limited cholesterol synthetic flux and lower CoA content.
• Atorvastatin treatment influences CoA synthesis and cholesterol storage dynamics in sensitive cells.
• These findings offer insights into mechanisms of statin sensitivity and resistance in cancer therapy.